C-reactive protein and neutrophil-lymphocyte ratio as predictors of mortality in coronavirus disease 2019
Rev. Assoc. Med. Bras. (1992)
; 67(10): 1498-1502, Oct. 2021. tab
Artículo
en Inglés
| LILACS
| ID: biblio-1351440
Biblioteca responsable:
BR1.1
ABSTRACT
SUMMARY OBJECTIVE:
This study investigates whether C-reactive protein, platelet-lymphocyte ratio, and neutrophil-lymphocyte ratio could be useful to predict mortality in COVID-19.METHODS:
Data of 635 patients with COVID-19 followed up in Sinop Ataturk State Hospital from February to May 2020 were evaluated retrospectively. Diagnosis of COVID-19 was made according to the interim guidance of the World Health Organization. Patients were grouped into two groups based on mortality as survived and non-survived patients. Age, gender, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein of the groups were investigated and compared.RESULTS:
The mean age of the participants was 55.8±22.3 years. Among the patients, 584 survived and 51 patients died. Age was significantly different between the groups, 54.2±22.3 in the survived group and 75.6±11.1 in the dead group (p=0.000). In addition, neutrophil, C-reactive protein, and neutrophil-lymphocyte ratio values were significantly higher in the dead group (p=0.000). platelet-lymphocyte ratio was slightly higher in the dead group, but this difference was not significant (p=0.42). The area under the curve values for age, lymphocyte, platelet, C-reactive protein, and neutrophil-lymphocyte ratio are 0.797, 0.424, 0.485, 0.778, and 0.729, respectively.CONCLUSIONS:
Our results showed that neutrophil-lymphocyte ratio and C-reactive protein are significantly higher in patients leading to death and could be effective biomarkers in predicting COVID-19 fatality. Furthermore, C-reactive protein could be used as an independent biomarker to predict death in patients with COVID-19, regardless of gender and age (p=0.000).
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Contexto en salud:
ODS3 - Salud y Bienestar
/
ODS3 - Meta 3.3 Poner fin a las enfermedades desatendidas y detener enfermedades transmisibles
/
ODS3 - Meta 3.4 Reducir las muertes prematuras por enfermedades no transmisibles
Problema de salud:
Meta 3.8: Alcanzar cobertura universal de salud
/
Neumonía
/
Otras Enfermedades Hematológicas
/
Otras Enfermedades Respiratorias
Base de datos:
LILACS
Asunto principal:
Proteína C-Reactiva
/
Linfocitos
/
COVID-19
/
Neutrófilos
Tipo de estudio:
Guía de práctica clínica
/
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Anciano
/
Humanos
Idioma:
Inglés
Revista:
Rev. Assoc. Med. Bras. (1992)
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Turquía
Institución/País de afiliación:
Abant Izzet Baysal University/TR
/
Atatürk Public Hospital/TR
/
Ayancik State Hospital/TR
/
Gazi State Hospital/TR